Amotiv Limited (AOV) - Total Liabilities

Latest as of September 2025: CA$281.78 Million CAD ≈ $203.84 Million USD

Based on the latest financial reports, Amotiv Limited (AOV) has total liabilities worth CA$281.78 Million CAD (≈ $203.84 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AOV operating cash flow to assess how effectively this company generates cash.

Amotiv Limited - Total Liabilities Trend (2014–2024)

This chart illustrates how Amotiv Limited's total liabilities have evolved over time, based on quarterly financial data. Check AOV cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Amotiv Limited Competitors by Total Liabilities

The table below lists competitors of Amotiv Limited ranked by their total liabilities.

Company Country Total Liabilities
Liberty Gold Corp
TO:LGD
Canada CA$6.55 Million
Red Violet Inc
NASDAQ:RDVT
USA $10.34 Million
Guangzhou Lushan New Materials Co. Ltd.
SHG:603051
China CN¥888.15 Million
CJ CGV
KO:079160
Korea ₩3.53 Trillion
Pepper Money Ltd
AU:PPM
Australia AU$16.37 Billion
CyberPower Systems Inc
TW:3617
Taiwan NT$4.51 Billion
Shanghai SK Petroleum & Chemical Equipment Corp Ltd
SHE:002278
China CN¥622.46 Million
Guaranty Bancshares, Inc.
NYSE:GNTY
USA $2.81 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Amotiv Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AOV company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.62 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.05 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Amotiv Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Amotiv Limited (2014–2024)

The table below shows the annual total liabilities of Amotiv Limited from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 CA$168.69 Million
≈ $122.03 Million
-15.07%
2023-12-31 CA$198.62 Million
≈ $143.68 Million
-13.26%
2022-12-31 CA$228.98 Million
≈ $165.64 Million
+52.78%
2021-12-31 CA$149.87 Million
≈ $108.42 Million
-2.32%
2020-12-31 CA$153.44 Million
≈ $110.99 Million
-60.68%
2019-12-31 CA$390.20 Million
≈ $282.26 Million
+1689.89%
2018-12-31 CA$21.80 Million
≈ $15.77 Million
+47.55%
2017-12-31 CA$14.78 Million
≈ $10.69 Million
+33.69%
2016-12-31 CA$11.05 Million
≈ $7.99 Million
+59.57%
2015-12-31 CA$6.93 Million
≈ $5.01 Million
-9.14%
2014-12-31 CA$7.62 Million
≈ $5.51 Million
--

About Amotiv Limited

TO:AOV Canada Drug Manufacturers - Specialty & Generic
Market Cap
$553.67 Million
CA$765.39 Million CAD
Market Cap Rank
#12003 Global
#343 in Canada
Share Price
CA$7.55
Change (1 day)
+0.67%
52-Week Range
CA$5.68 - CA$7.74
All Time High
CA$10.90
About

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more